{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:35:48Z","timestamp":1794828948897,"version":"4.9.1"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41573-025-01234-0","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:02:06Z","timestamp":1751241726000},"page":"852-869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Targeting the Hippo pathway in cancer"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-369X","authenticated-orcid":false,"given":"Kieran F.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1234_CR1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(02)00824-3","volume":"110","author":"N Tapon","year":"2002","unstructured":"Tapon, N. et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110, 467\u2013478 (2002).","journal-title":"Cell"},{"key":"1234_CR2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ncb1051","volume":"5","author":"S Pantalacci","year":"2003","unstructured":"Pantalacci, S., Tapon, N. & Leopold, P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat. Cell Biol. 5, 921\u2013927 (2003).","journal-title":"Nat. Cell Biol."},{"key":"1234_CR3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1101\/gad.9.5.534","volume":"9","author":"RW Justice","year":"1995","unstructured":"Justice, R. W., Zilian, O., Woods, D. F., Noll, M. & Bryant, P. J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9, 534\u2013546 (1995).","journal-title":"Genes Dev."},{"key":"1234_CR4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1242\/dev.121.4.1053","volume":"121","author":"T Xu","year":"1995","unstructured":"Xu, T., Wang, W., Zhang, S., Stewart, R. A. & Yu, W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053\u20131063 (1995).","journal-title":"Development"},{"key":"1234_CR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0092-8674(03)00549-X","volume":"114","author":"S Wu","year":"2003","unstructured":"Wu, S., Huang, J., Dong, J. & Pan, D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and Warts. Cell 114, 445\u2013456 (2003).","journal-title":"Cell"},{"key":"1234_CR6","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1101\/gad.1134003","volume":"17","author":"J Jia","year":"2003","unstructured":"Jia, J., Zhang, W., Wang, B., Trinko, R. & Jiang, J. The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 17, 2514\u20132519 (2003).","journal-title":"Genes Dev."},{"key":"1234_CR7","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1242\/dev.00168","volume":"129","author":"M Kango-Singh","year":"2002","unstructured":"Kango-Singh, M. et al. Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development 129, 5719\u20135730 (2002).","journal-title":"Development"},{"key":"1234_CR8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ncb1050","volume":"5","author":"RS Udan","year":"2003","unstructured":"Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C. & Halder, G. Hippo promotes proliferation arrest and apoptosis in the Salvador\/Warts pathway. Nat. Cell Biol. 5, 914\u2013920 (2003).","journal-title":"Nat. Cell Biol."},{"key":"1234_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0092-8674(03)00557-9","volume":"114","author":"KF Harvey","year":"2003","unstructured":"Harvey, K. F., Pfleger, C. M. & Hariharan, I. K. The Drosophila MST ortholog, Hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114, 457\u2013467 (2003).","journal-title":"Cell"},{"key":"1234_CR10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ceb.2014.09.003","volume":"31C","author":"P Gaspar","year":"2014","unstructured":"Gaspar, P. & Tapon, N. Sensing the local environment: actin architecture and Hippo signalling. Curr. Opin. Cell Biol. 31C, 74\u201383 (2014).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1234_CR11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","volume":"50","author":"Y Zheng","year":"2019","unstructured":"Zheng, Y. & Pan, D. The Hippo signaling pathway in development and disease. Dev. Cell 50, 264\u2013282 (2019).","journal-title":"Dev. Cell"},{"key":"1234_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.274027.115","volume":"30","author":"Z Meng","year":"2016","unstructured":"Meng, Z., Moroishi, T. & Guan, K. L. Mechanisms of Hippo pathway regulation. Genes Dev. 30, 1\u201317 (2016).","journal-title":"Genes Dev."},{"key":"1234_CR13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"Moya, I. M. & Halder, G. Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol. 20, 211\u2013226 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1234_CR14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246\u2013257 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1234_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/dvdy.22723","volume":"241","author":"BK Staley","year":"2012","unstructured":"Staley, B. K. & Irvine, K. D. Hippo signaling in Drosophila: recent advances and insights. Dev. Dyn. 241, 3\u201315 (2012).","journal-title":"Dev. Dyn."},{"key":"1234_CR16","doi-asserted-by":"crossref","first-page":"re7","DOI":"10.1126\/scisignal.2004208","volume":"6","author":"L Enderle","year":"2013","unstructured":"Enderle, L. & McNeill, H. Hippo gains weight: added insights and complexity to pathway control. Sci. Signal. 6, re7 (2013).","journal-title":"Sci. Signal."},{"key":"1234_CR17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","volume":"122","author":"J Huang","year":"2005","unstructured":"Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122, 421\u2013434 (2005).","journal-title":"Cell"},{"key":"1234_CR18","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120\u20131133 (2007).","journal-title":"Cell"},{"key":"1234_CR19","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747\u20132761 (2007).","journal-title":"Genes Dev."},{"key":"1234_CR20","doi-asserted-by":"crossref","first-page":"27534","DOI":"10.1074\/jbc.M804380200","volume":"283","author":"T Oka","year":"2008","unstructured":"Oka, T., Mazack, V. & Sudol, M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J. Biol. Chem. 283, 27534\u201327546 (2008).","journal-title":"J. Biol. Chem."},{"key":"1234_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.celrep.2011.11.004","volume":"1","author":"A Seb\u00e9-Pedr\u00f3s","year":"2012","unstructured":"Seb\u00e9-Pedr\u00f3s, A., Zheng, Y., Ruiz-Trillo, I. & Pan, D. Premetazoan origin of the Hippo signaling pathway. Cell Rep. 1, 13\u201320 (2012).","journal-title":"Cell Rep."},{"key":"1234_CR22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/molbev\/msu071","volume":"31","author":"A Ikmi","year":"2014","unstructured":"Ikmi, A. et al. Molecular evolution of the Yap\/Yorkie proto-oncogene and elucidation of its core transcriptional program. Mol. Biol. Evol. 31, 1375\u20131390 (2014).","journal-title":"Mol. Biol. Evol."},{"key":"1234_CR23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2005.07.026","volume":"122","author":"T Mikeladze-Dvali","year":"2005","unstructured":"Mikeladze-Dvali, T. et al. The growth regulators warts\/lats and melted interact in a bistable loop to specify opposite fates in Drosophila R8 photoreceptors. Cell 122, 775\u2013787 (2005).","journal-title":"Cell"},{"key":"1234_CR24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.devcel.2009.02.003","volume":"16","author":"N Nishioka","year":"2009","unstructured":"Nishioka, N. et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398\u2013410 (2009).","journal-title":"Dev. Cell"},{"key":"1234_CR25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. Cell Rep. 25, 1304\u20131317.e1305 (2018).","journal-title":"Cell Rep."},{"key":"1234_CR26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.trecan.2020.04.004","volume":"6","author":"A Kulkarni","year":"2020","unstructured":"Kulkarni, A., Chang, M. T., Vissers, J. H. A., Dey, A. & Harvey, K. F. The Hippo pathway as a driver of select human cancers. Trends Cancer 6, 781\u2013796 (2020).","journal-title":"Trends Cancer"},{"key":"1234_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2009.09.026","volume":"16","author":"D Zhou","year":"2009","unstructured":"Zhou, D. et al. MST1 and MST2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the YAP1 oncogene. Cancer Cell 16, 425\u2013438 (2009).","journal-title":"Cancer Cell"},{"key":"1234_CR28","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo, F. D. et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17, 2054\u20132060 (2007).","journal-title":"Curr. Biol."},{"key":"1234_CR29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/emboj.2008.63","volume":"27","author":"JH Lee","year":"2008","unstructured":"Lee, J. H. et al. A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J. 27, 1231\u20131242 (2008).","journal-title":"EMBO J."},{"key":"1234_CR30","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/j.devcel.2023.11.002","volume":"58","author":"S Kobayashi","year":"2023","unstructured":"Kobayashi, S., Cox, A. G., Harvey, K. F. & Hogan, B. M. Vasculature is getting Hip(po): Hippo signaling in vascular development and disease. Dev. Cell 58, 2627\u20132640 (2023).","journal-title":"Dev. Cell"},{"key":"1234_CR31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.1199010","volume":"332","author":"T Heallen","year":"2011","unstructured":"Heallen, T. et al. Hippo pathway inhibits WNT signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458\u2013461 (2011).","journal-title":"Science"},{"key":"1234_CR32","volume":"6","author":"KI Watt","year":"2015","unstructured":"Watt, K. I. et al. The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. Nat. Commun. 6, 6048 (2015).","journal-title":"Nat. Commun."},{"key":"1234_CR33","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1101\/gad.1726608","volume":"22","author":"X Cao","year":"2008","unstructured":"Cao, X., Pfaff, S. L. & Gage, F. H. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev. 22, 3320\u20133334 (2008).","journal-title":"Genes Dev."},{"key":"1234_CR34","doi-asserted-by":"crossref","DOI":"10.1126\/science.1238016","volume":"342","author":"D Jukam","year":"2013","unstructured":"Jukam, D. et al. Opposite feedbacks in the Hippo pathway for growth control and neural fate. Science 342, 1238016 (2013).","journal-title":"Science"},{"key":"1234_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102830","volume":"24","author":"JM Pojer","year":"2021","unstructured":"Pojer, J. M., Manning, S. A., Kroeger, B., Kondo, S. & Harvey, K. F. The Hippo pathway uses different machinery to control cell fate and organ size. iScience 24, 102830 (2021).","journal-title":"iScience"},{"key":"1234_CR36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009146","volume":"17","author":"JM Pojer","year":"2021","unstructured":"Pojer, J. M., Saiful Hilmi, A. J., Kondo, S. & Harvey, K. F. Crumbs and the apical spectrin cytoskeleton regulate R8 cell fate in the Drosophila eye. PLoS Genet. 17, e1009146 (2021).","journal-title":"PLoS Genet."},{"key":"1234_CR37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.devcel.2011.10.004","volume":"21","author":"D Jukam","year":"2011","unstructured":"Jukam, D. & Desplan, C. Binary regulation of Hippo pathway by Merlin\/NF2, Kibra, Lgl, and Melted specifies and maintains postmitotic neuronal fate. Dev. Cell 21, 874\u2013887 (2011).","journal-title":"Dev. Cell"},{"key":"1234_CR38","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3679","volume":"378","author":"W Kowalczyk","year":"2022","unstructured":"Kowalczyk, W. et al. Hippo signaling instructs ectopic but not normal organ growth. Science 378, eabg3679 (2022).","journal-title":"Science"},{"key":"1234_CR39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrm3416","volume":"13","author":"G Halder","year":"2012","unstructured":"Halder, G., Dupont, S. & Piccolo, S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 13, 591\u2013600 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1234_CR40","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.tcb.2016.05.003","volume":"26","author":"S Sun","year":"2016","unstructured":"Sun, S. & Irvine, K. D. Cellular organization and cytoskeletal regulation of the Hippo signaling network. Trends Cell Biol. 26, 694\u2013704 (2016).","journal-title":"Trends Cell Biol."},{"key":"1234_CR41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013183 (2011).","journal-title":"Nature"},{"key":"1234_CR42","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1242\/dev.070987","volume":"138","author":"K Wada","year":"2011","unstructured":"Wada, K., Itoga, K., Okano, T., Yonemura, S. & Sasaki, H. Hippo pathway regulation by cell morphology and stress fibers. Development 138, 3907\u20133914 (2011).","journal-title":"Development"},{"key":"1234_CR43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cell.2014.05.035","volume":"158","author":"C Rauskolb","year":"2014","unstructured":"Rauskolb, C., Sun, S., Sun, G., Pan, Y. & Irvine, K. D. Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex. Cell 158, 143\u2013156 (2014).","journal-title":"Cell"},{"key":"1234_CR44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.celrep.2013.01.008","volume":"3","author":"H Oh","year":"2013","unstructured":"Oh, H. et al. Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. Cell Rep. 3, 309\u2013318 (2013).","journal-title":"Cell Rep."},{"key":"1234_CR45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.celrep.2014.06.017","volume":"8","author":"H Oh","year":"2014","unstructured":"Oh, H. et al. Yorkie promotes transcription by recruiting a histone methyltransferase complex. Cell Rep. 8, 449\u2013459 (2014).","journal-title":"Cell Rep."},{"key":"1234_CR46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02564","volume":"3","author":"Y Qing","year":"2014","unstructured":"Qing, Y. et al. The Hippo effector Yorkie activates transcription by interacting with a histone methyltransferase complex through Ncoa6. eLife 3, e02564 (2014).","journal-title":"eLife"},{"key":"1234_CR47","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato, F. et al. Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17, 1218\u20131227 (2015).","journal-title":"Nat. Cell Biol."},{"key":"1234_CR48","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molcel.2015.09.001","volume":"60","author":"GG Galli","year":"2015","unstructured":"Galli, G. G. et al. YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol. Cell 60, 328\u2013337 (2015).","journal-title":"Mol. Cell"},{"key":"1234_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cub.2008.02.034","volume":"18","author":"Y Goulev","year":"2008","unstructured":"Goulev, Y. et al. Scalloped interacts with Yorkie, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr. Biol. 18, 435\u2013441 (2008).","journal-title":"Curr. Biol."},{"key":"1234_CR50","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1242\/dev.027151","volume":"135","author":"M Ota","year":"2008","unstructured":"Ota, M. & Sasaki, H. Mammalian tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 135, 4059\u20134069 (2008).","journal-title":"Development"},{"key":"1234_CR51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.devcel.2008.01.007","volume":"14","author":"S Wu","year":"2008","unstructured":"Wu, S., Liu, Y., Zheng, Y., Dong, J. & Pan, D. The TEAD\/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev. Cell 14, 388\u2013398 (2008).","journal-title":"Dev. Cell"},{"key":"1234_CR52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.devcel.2008.01.006","volume":"14","author":"L Zhang","year":"2008","unstructured":"Zhang, L. et al. The TEAD\/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev. Cell 14, 377\u2013387 (2008).","journal-title":"Dev. Cell"},{"key":"1234_CR53","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","volume":"22","author":"B Zhao","year":"2008","unstructured":"Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962\u20131971 (2008).","journal-title":"Genes Dev."},{"key":"1234_CR54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.devcel.2013.04.021","volume":"25","author":"LM Koontz","year":"2013","unstructured":"Koontz, L. M. et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing Scalloped-mediated default repression. Dev. Cell 25, 388\u2013401 (2013).","journal-title":"Dev. Cell"},{"key":"1234_CR55","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/cr.2013.120","volume":"23","author":"T Guo","year":"2013","unstructured":"Guo, T. et al. A novel partner of Scalloped regulates Hippo signaling via antagonizing Scalloped-Yorkie activity. Cell Res. 23, 1201\u20131214 (2013).","journal-title":"Cell Res."},{"key":"1234_CR56","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.celrep.2018.10.038","volume":"25","author":"JHA Vissers","year":"2018","unstructured":"Vissers, J. H. A. et al. The Scalloped and Nerfin-1 transcription factors cooperate to maintain neuronal cell fate. Cell Rep. 25, 1561\u20131576.e1567 (2018).","journal-title":"Cell Rep."},{"key":"1234_CR57","volume":"8","author":"P Guo","year":"2019","unstructured":"Guo, P. et al. Nerfin-1 represses transcriptional output of Hippo signaling in cell competition. eLife 8, e38843 (2019).","journal-title":"eLife"},{"key":"1234_CR58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1534\/genetics.120.303147","volume":"215","author":"JHA Vissers","year":"2020","unstructured":"Vissers, J. H. A., Dent, L. G., House, C. M., Kondo, S. & Harvey, K. F. Pits and CtBP control tissue growth in Drosophila melanogaster with the Hippo pathway transcription repressor Tgi. Genetics 215, 117\u2013128 (2020).","journal-title":"Genetics"},{"key":"1234_CR59","doi-asserted-by":"crossref","first-page":"17119","DOI":"10.1074\/jbc.RA118.003608","volume":"293","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex. J. Biol. Chem. 293, 17119\u201317134 (2018).","journal-title":"J. Biol. Chem."},{"key":"1234_CR60","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.devcel.2024.04.006","volume":"59","author":"SA Manning","year":"2024","unstructured":"Manning, S. A. et al. The Drosophila Hippo pathway transcription factor Scalloped and its co-factors alter each other\u2019s chromatin binding dynamics and transcription in vivo. Dev. Cell 59, 1640\u20131654.e1645 (2024).","journal-title":"Dev. Cell"},{"key":"1234_CR61","doi-asserted-by":"publisher","unstructured":"Kroeger, B. et al. Hippo signalling regulates the nuclear behaviour and DNA dwell times of YAP and TEAD to control transcription. Preprint at https:\/\/doi.org\/10.1101\/2025.03.11.642705 (2025).","DOI":"10.1101\/2025.03.11.642705"},{"key":"1234_CR62","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.5781","volume":"255","author":"K Asrani","year":"2021","unstructured":"Asrani, K. et al. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. J. Pathol. 255, 425\u2013437 (2021).","journal-title":"J. Pathol."},{"key":"1234_CR63","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1101\/gad.12.24.3900","volume":"12","author":"G Halder","year":"1998","unstructured":"Halder, G. et al. The Vestigial and Scalloped proteins act together to directly regulate wing-specific gene expression in Drosophila. Genes Dev. 12, 3900\u20133909 (1998).","journal-title":"Genes Dev."},{"key":"1234_CR64","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s004270050201","volume":"208","author":"S Paumard-Rigal","year":"1998","unstructured":"Paumard-Rigal, S., Zider, A., Vaudin, P. & Silber, J. Specific interactions between Vestigial and Scalloped are required to promote wing tissue proliferation in Drosophila melanogaster. Dev. Genes Evol. 208, 440\u2013446 (1998).","journal-title":"Dev. Genes Evol."},{"key":"1234_CR65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/01677069809167258","volume":"12","author":"A Zider","year":"1998","unstructured":"Zider, A., Paumard-Rigal, S., Frouin, I. & Silber, J. The vestigial gene of Drosophila melanogaster is involved in the formation of the peripheral nervous system: genetic interactions with the scute gene. J. Neurogenet. 12, 87\u201399 (1998).","journal-title":"J. Neurogenet."},{"key":"1234_CR66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188892","volume":"1878","author":"HM Sonnemann","year":"2023","unstructured":"Sonnemann, H. M., Pazdrak, B., Antunes, D. A., Roszik, J. & Lizee, G. Vestigial-like 1 (VGLL1): an ancient co-transcriptional activator linking wing, placenta, and tumor development. Biochim. Biophys. Acta Rev. Cancer 1878, 188892 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1234_CR67","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1101\/gad.12.24.3815","volume":"12","author":"AJ Simmonds","year":"1998","unstructured":"Simmonds, A. J. et al. Molecular interactions between Vestigial and Scalloped promote wing formation in Drosophila. Genes Dev. 12, 3815\u20133820 (1998).","journal-title":"Genes Dev."},{"key":"1234_CR68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cell.2004.12.036","volume":"120","author":"ZC Lai","year":"2005","unstructured":"Lai, Z. C. et al. Control of cell proliferation and apoptosis by Mob as tumor suppressor, Mats. Cell 120, 675\u2013685 (2005).","journal-title":"Cell"},{"key":"1234_CR69","volume":"6","author":"Z Meng","year":"2015","unstructured":"Meng, Z. et al. MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway. Nat. Commun. 6, 8357 (2015).","journal-title":"Nat. Commun."},{"key":"1234_CR70","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.devcel.2015.08.014","volume":"34","author":"Y Zheng","year":"2015","unstructured":"Zheng, Y. et al. Identification of Happyhour\/MAP4K as alternative Hpo\/Mst-like kinases in the Hippo kinase cascade. Dev. Cell 34, 642\u2013655 (2015).","journal-title":"Dev. Cell"},{"key":"1234_CR71","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.devcel.2011.08.028","volume":"21","author":"JC Boggiano","year":"2011","unstructured":"Boggiano, J. C., Vanderzalm, P. J. & Fehon, R. G. Tao-1 phosphorylates Hippo\/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev. Cell 21, 888\u2013895 (2011).","journal-title":"Dev. Cell"},{"key":"1234_CR72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.devcel.2011.09.012","volume":"21","author":"CL Poon","year":"2011","unstructured":"Poon, C. L., Lin, J. I., Zhang, X. & Harvey, K. F. The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev. Cell 21, 896\u2013906 (2011).","journal-title":"Dev. Cell"},{"key":"1234_CR73","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molcel.2010.08.002","volume":"39","author":"PS Ribeiro","year":"2010","unstructured":"Ribeiro, P. S. et al. Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol. Cell 39, 521\u2013534 (2010).","journal-title":"Mol. Cell"},{"key":"1234_CR74","doi-asserted-by":"crossref","first-page":"R574","DOI":"10.1016\/j.cub.2010.05.023","volume":"20","author":"FA Grusche","year":"2010","unstructured":"Grusche, F. A., Richardson, H. E. & Harvey, K. F. Upstream regulation of the Hippo size control pathway. Curr. Biol. 20, R574\u2013R582 (2010).","journal-title":"Curr. Biol."},{"key":"1234_CR75","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.devcel.2017.02.004","volume":"40","author":"T Su","year":"2017","unstructured":"Su, T., Ludwig, M. Z., Xu, J. & Fehon, R. G. Kibra and Merlin activate the Hippo pathway spatially distinct from and independent of Expanded. Dev. Cell 40, 478\u2013490.e473 (2017).","journal-title":"Dev. Cell"},{"key":"1234_CR76","volume":"6","author":"S Sun","year":"2015","unstructured":"Sun, S., Reddy, B. V. & Irvine, K. D. Localization of Hippo signalling complexes and Warts activation in vivo. Nat. Commun. 6, 8402 (2015).","journal-title":"Nat. Commun."},{"key":"1234_CR77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/onc.2011.224","volume":"31","author":"L Angus","year":"2012","unstructured":"Angus, L. et al. Willin\/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 31, 238\u2013250 (2012).","journal-title":"Oncogene"},{"key":"1234_CR78","volume":"385","author":"P Guo","year":"2024","unstructured":"Guo, P. et al. PI4P-mediated solid-like Merlin condensates orchestrate Hippo pathway regulation. Science 385, eadf4478 (2024).","journal-title":"Science"},{"key":"1234_CR79","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41589-022-01061-z","volume":"18","author":"FL Li","year":"2022","unstructured":"Li, F. L. et al. Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nat. Chem. Biol. 18, 1076\u20131086 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1234_CR80","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cub.2010.01.055","volume":"20","author":"NA Grzeschik","year":"2010","unstructured":"Grzeschik, N. A., Parsons, L. M., Allott, M. L., Harvey, K. F. & Richardson, H. E. Lgl, aPKC, and Crumbs regulate the Salvador\/Warts\/Hippo pathway through two distinct mechanisms. Curr. Biol. 20, 573\u2013581 (2010).","journal-title":"Curr. Biol."},{"key":"1234_CR81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","volume":"147","author":"M Cordenonsi","year":"2011","unstructured":"Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759\u2013772 (2011).","journal-title":"Cell"},{"key":"1234_CR82","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cub.2010.03.019","volume":"20","author":"BS Robinson","year":"2010","unstructured":"Robinson, B. S., Huang, J., Hong, Y. & Moberg, K. H. Crumbs regulates Salvador\/Warts\/Hippo signaling in Drosophila via the FERM-domain protein expanded. Curr. Biol. 20, 582\u2013590 (2010).","journal-title":"Curr. Biol."},{"key":"1234_CR83","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1073\/pnas.1004279107","volume":"107","author":"C Ling","year":"2010","unstructured":"Ling, C. et al. The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. Proc. Natl Acad. Sci. USA 107, 10532\u201310537 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1234_CR84","doi-asserted-by":"crossref","first-page":"15810","DOI":"10.1073\/pnas.1004060107","volume":"107","author":"CL Chen","year":"2010","unstructured":"Chen, C. L. et al. The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. Proc. Natl Acad. Sci. USA 107, 15810\u201315815 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1234_CR85","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.devcel.2010.11.012","volume":"19","author":"X Varelas","year":"2010","unstructured":"Varelas, X. et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev. Cell 19, 831\u2013844 (2010).","journal-title":"Dev. Cell"},{"key":"1234_CR86","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/onc.2013.82","volume":"33","author":"W Bossuyt","year":"2014","unstructured":"Bossuyt, W. et al. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene 33, 1218\u20131228 (2014).","journal-title":"Oncogene"},{"key":"1234_CR87","volume":"119","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway. Proc. Natl Acad. Sci. USA 119, e2121779119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1234_CR88","volume":"40","author":"Y Gu","year":"2022","unstructured":"Gu, Y. et al. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP\/TAZ-active cancers. Cell Rep. 40, 111296 (2022).","journal-title":"Cell Rep."},{"key":"1234_CR89","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06567","volume":"4","author":"H Deng","year":"2015","unstructured":"Deng, H. et al. Spectrin regulates Hippo signaling by modulating cortical actomyosin activity. eLife 4, e06567 (2015).","journal-title":"eLife"},{"key":"1234_CR90","doi-asserted-by":"crossref","first-page":"940","DOI":"10.15252\/embj.201489642","volume":"34","author":"GC Fletcher","year":"2015","unstructured":"Fletcher, G. C. et al. The spectrin cytoskeleton regulates the Hippo signalling pathway. EMBO J. 34, 940\u2013954 (2015).","journal-title":"EMBO J."},{"key":"1234_CR91","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1074\/jbc.M114.629493","volume":"290","author":"KK Wong","year":"2015","unstructured":"Wong, K. K. et al. \u03b2-Spectrin regulates the hippo signaling pathway and modulates the basal actin network. J. Biol. Chem. 290, 6397\u20136407 (2015).","journal-title":"J. Biol. Chem."},{"key":"1234_CR92","doi-asserted-by":"crossref","first-page":"RP84918","DOI":"10.7554\/eLife.84918.3","volume":"12","author":"C Ibar","year":"2023","unstructured":"Ibar, C., Chinthalapudi, K., Heissler, S. M. & Irvine, K. D. Competition between myosin II and beta(H)-spectrin regulates cytoskeletal tension. eLife 12, RP84918 (2023).","journal-title":"eLife"},{"key":"1234_CR93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ydbio.2007.02.004","volume":"305","author":"DM Tyler","year":"2007","unstructured":"Tyler, D. M. & Baker, N. E. Expanded and Fat regulate growth and differentiation in the Drosophila eye through multiple signaling pathways. Dev. Biol. 305, 187\u2013201 (2007).","journal-title":"Dev. Biol."},{"key":"1234_CR94","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.cub.2006.09.005","volume":"16","author":"M Willecke","year":"2006","unstructured":"Willecke, M. et al. The Fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr. Biol. 16, 2090\u20132100 (2006).","journal-title":"Curr. Biol."},{"key":"1234_CR95","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.cub.2006.09.004","volume":"16","author":"E Silva","year":"2006","unstructured":"Silva, E., Tsatskis, Y., Gardano, L., Tapon, N. & McNeill, H. The tumor-suppressor gene Fat controls tissue growth upstream of expanded in the Hippo signaling pathway. Curr. Biol. 16, 2081\u20132089 (2006).","journal-title":"Curr. Biol."},{"key":"1234_CR96","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ng1887","volume":"38","author":"E Cho","year":"2006","unstructured":"Cho, E. et al. Delineation of a Fat tumor suppressor pathway. Nat. Genet. 38, 1142\u20131150 (2006).","journal-title":"Nat. Genet."},{"key":"1234_CR97","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.cub.2006.09.045","volume":"16","author":"FC Bennett","year":"2006","unstructured":"Bennett, F. C. & Harvey, K. F. Fat cadherin modulates organ size in Drosophila via the Salvador\/Warts\/Hippo signaling pathway. Curr. Biol. 16, 2101\u20132110 (2006).","journal-title":"Curr. Biol."},{"key":"1234_CR98","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.842593","volume":"10","author":"A Gridnev","year":"2022","unstructured":"Gridnev, A. & Misra, J. R. Emerging mechanisms of growth and patterning regulation by Dachsous and Fat protocadherins. Front. Cell Dev. Biol. 10, 842593 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1234_CR99","volume":"9","author":"D Martin","year":"2018","unstructured":"Martin, D. et al. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Nat. Commun. 9, 2372 (2018).","journal-title":"Nat. Commun."},{"key":"1234_CR100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41556-024-01558-w","volume":"27","author":"WT Lu","year":"2025","unstructured":"Lu, W. T. et al. TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling. Nat. Cell Biol. 27, 154\u2013168 (2025).","journal-title":"Nat. Cell Biol."},{"key":"1234_CR101","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cub.2010.02.035","volume":"20","author":"M Das Thakur","year":"2010","unstructured":"Das Thakur, M. et al. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr. Biol. 20, 657\u2013662 (2010).","journal-title":"Curr. Biol."},{"key":"1234_CR102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.devcel.2023.11.024","volume":"59","author":"B Kroeger","year":"2024","unstructured":"Kroeger, B. et al. Basal spot junctions of Drosophila epithelial tissues respond to morphogenetic forces and regulate Hippo signaling. Dev. Cell 59, 262\u2013279.e266 (2024).","journal-title":"Dev. Cell"},{"key":"1234_CR103","doi-asserted-by":"crossref","first-page":"jcs214700","DOI":"10.1242\/jcs.214700","volume":"131","author":"C Ibar","year":"2018","unstructured":"Ibar, C. et al. Tension-dependent regulation of mammalian Hippo signaling through LIMD1. J. Cell Sci. 131, jcs214700 (2018).","journal-title":"J. Cell Sci."},{"key":"1234_CR104","volume":"11","author":"HL Huang","year":"2013","unstructured":"Huang, H. L. et al. Par-1 regulates tissue growth by influencing Hippo phosphorylation status and Hippo-Salvador association. PLoS Biol. 11, e1001620 (2013).","journal-title":"PLoS Biol."},{"key":"1234_CR105","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.E23-06-0246","volume":"35","author":"SA Tokamov","year":"2024","unstructured":"Tokamov, S. A. et al. Cortical tension promotes Kibra degradation via Par-1. Mol. Biol. Cell 35, ar2 (2024).","journal-title":"Mol. Biol. Cell"},{"key":"1234_CR106","doi-asserted-by":"crossref","first-page":"420","DOI":"10.15252\/embr.201642455","volume":"18","author":"E Heidary Arash","year":"2017","unstructured":"Heidary Arash, E., Shiban, A., Song, S. & Attisano, L. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. 18, 420\u2013436 (2017).","journal-title":"EMBO Rep."},{"key":"1234_CR107","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1101\/gad.284539.116","volume":"30","author":"J Kwan","year":"2016","unstructured":"Kwan, J. et al. DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1\/2. Genes Dev. 30, 2696\u20132709 (2016).","journal-title":"Genes Dev."},{"key":"1234_CR108","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/2159-8290.CD-23-1529","volume":"14","author":"O Klingbeil","year":"2024","unstructured":"Klingbeil, O. et al. MARK2\/MARK3 kinases are catalytic codependencies of YAP\/TAZ in human cancer. Cancer Discov. 14, 2471\u20132488 (2024).","journal-title":"Cancer Discov."},{"key":"1234_CR109","doi-asserted-by":"crossref","first-page":"20362","DOI":"10.1073\/pnas.0706722105","volume":"104","author":"Y Feng","year":"2007","unstructured":"Feng, Y. & Irvine, K. D. Fat and Expanded act in parallel to regulate growth through Warts. Proc. Natl Acad. Sci. USA 104, 20362\u201320367 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1234_CR110","volume":"42","author":"S Qi","year":"2023","unstructured":"Qi, S. et al. Two Hippo signaling modules orchestrate liver size and tumorigenesis. EMBO J. 42, e115749 (2023).","journal-title":"EMBO J."},{"key":"1234_CR111","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.devcel.2009.12.012","volume":"18","author":"J Yu","year":"2010","unstructured":"Yu, J. et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev. Cell 18, 288\u2013299 (2010).","journal-title":"Dev. Cell"},{"key":"1234_CR112","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.devcel.2009.12.011","volume":"18","author":"A Genevet","year":"2010","unstructured":"Genevet, A., Wehr, M. C., Brain, R., Thompson, B. J. & Tapon, N. Kibra is a regulator of the Salvador\/Warts\/Hippo signaling network. Dev. Cell 18, 300\u2013308 (2010).","journal-title":"Dev. Cell"},{"key":"1234_CR113","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.devcel.2009.12.013","volume":"18","author":"R Baumgartner","year":"2010","unstructured":"Baumgartner, R., Poernbacher, I., Buser, N., Hafen, E. & Stocker, H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev. Cell 18, 309\u2013316 (2010).","journal-title":"Dev. Cell"},{"key":"1234_CR114","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey, A., Varelas, X. & Guan, K. L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug Discov. 19, 480\u2013494 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1234_CR115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41569-018-0063-3","volume":"15","author":"J Wang","year":"2018","unstructured":"Wang, J., Liu, S., Heallen, T. & Martin, J. F. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat. Rev. Cardiol. 15, 672\u2013684 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1234_CR116","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli, A. M. & Fern\u00e1ndez-Valle, C. Role of Merlin\/NF2 inactivation in tumor biology. Oncogene 35, 537\u2013548 (2016).","journal-title":"Oncogene"},{"key":"1234_CR117","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/hmg\/ddh106","volume":"13","author":"R Fossdal","year":"2004","unstructured":"Fossdal, R. et al. A novel TEAD1 mutation is the causative allele in Sveinsson\u2019s chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum. Mol. Genet. 13, 975\u2013981 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"1234_CR118","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell 173, 321\u2013337.e310 (2018).","journal-title":"Cell"},{"key":"1234_CR119","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1234_CR120","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"1234_CR121","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami, H. et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71, 873\u2013883 (2011).","journal-title":"Cancer Res."},{"key":"1234_CR122","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","volume":"61","author":"Y Sekido","year":"2011","unstructured":"Sekido, Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol. Int. 61, 331\u2013344 (2011).","journal-title":"Pathol. Int."},{"key":"1234_CR123","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"1234_CR124","volume":"25","author":"P Markowitz","year":"2020","unstructured":"Markowitz, P. et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat. Res. Commun. 25, 100232 (2020).","journal-title":"Cancer Treat. Res. Commun."},{"key":"1234_CR125","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","volume":"5","author":"Y Sekido","year":"2023","unstructured":"Sekido, Y. & Sato, T. NF2 alteration in mesothelioma. Front. Toxicol. 5, 1161995 (2023).","journal-title":"Front. Toxicol."},{"key":"1234_CR126","doi-asserted-by":"crossref","first-page":"98ra82","DOI":"10.1126\/scitranslmed.3002409","volume":"3","author":"MR Tanas","year":"2011","unstructured":"Tanas, M. R. et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 3, 98ra82 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1234_CR127","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","volume":"50","author":"C Errani","year":"2011","unstructured":"Errani, C. et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50, 644\u2013653 (2011).","journal-title":"Genes Chromosomes Cancer"},{"key":"1234_CR128","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62857","volume":"10","author":"N Merritt","year":"2021","unstructured":"Merritt, N. et al. TAZ-CAMTA1 and YAP-TFE3 alter the TAZ\/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex. eLife 10, e62857 (2021).","journal-title":"eLife"},{"key":"1234_CR129","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.3390\/cancers14122980","volume":"14","author":"CN Seavey","year":"2022","unstructured":"Seavey, C. N., Pobbati, A. V. & Rubin, B. P. Unraveling the biology of epithelioid hemangioendothelioma, a TAZ-CAMTA1 fusion driven sarcoma. Cancers 14, 2980 (2022).","journal-title":"Cancers"},{"key":"1234_CR130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.trecan.2022.08.002","volume":"8","author":"K Garcia","year":"2022","unstructured":"Garcia, K., Gingras, A. C., Harvey, K. F. & Tanas, M. R. TAZ\/YAP fusion proteins: mechanistic insights and therapeutic opportunities. Trends Cancer 8, 1033\u20131045 (2022).","journal-title":"Trends Cancer"},{"key":"1234_CR131","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/gcc.23083","volume":"61","author":"A Agaimy","year":"2022","unstructured":"Agaimy, A. et al. Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck. Genes Chromosomes Cancer 61, 701\u2013709 (2022).","journal-title":"Genes Chromosomes Cancer"},{"key":"1234_CR132","doi-asserted-by":"crossref","first-page":"98386","DOI":"10.7554\/eLife.98386","volume":"13","author":"S Guo","year":"2022","unstructured":"Guo, S. et al. VGLL2 and TEAD1 fusion proteins identified in human sarcoma drive YAP\/TAZ-independent tumorigenesis by engaging EP300. eLife 13, 98386 (2025).","journal-title":"eLife"},{"key":"1234_CR133","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ccell.2021.06.016","volume":"39","author":"JD Pearson","year":"2021","unstructured":"Pearson, J. D. et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP\/TEAD activity. Cancer Cell 39, 1115\u20131134.e1112 (2021).","journal-title":"Cancer Cell"},{"key":"1234_CR134","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1234_CR135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen, C. D. K. & Yi, C. YAP\/TAZ signaling and resistance to cancer therapy. Trends Cancer 5, 283\u2013296 (2019).","journal-title":"Trends Cancer"},{"key":"1234_CR136","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"1234_CR137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","volume":"158","author":"DD Shao","year":"2014","unstructured":"Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171\u2013184 (2014).","journal-title":"Cell"},{"key":"1234_CR138","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250\u2013256 (2015).","journal-title":"Nat. Genet."},{"key":"1234_CR139","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek, T. J. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023).","journal-title":"Nat. Cancer"},{"key":"1234_CR140","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/0008-5472.CAN-23-2729","volume":"83","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay, S. et al. Genome-wide CRISPR screens identify multiple synthetic lethal targets that enhance KRASG12C inhibitor efficacy. Cancer Res. 83, 4095\u20134111 (2023).","journal-title":"Cancer Res."},{"key":"1234_CR141","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.trecan.2023.11.003","volume":"10","author":"CJ Tape","year":"2024","unstructured":"Tape, C. J. Plastic persisters: revival stem cells in colorectal cancer. Trends Cancer 10, 185\u2013195 (2024).","journal-title":"Trends Cancer"},{"key":"1234_CR142","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/2159-8290.CD-19-1536","volume":"10","author":"T Han","year":"2020","unstructured":"Han, T. et al. Lineage reversion drives WNT independence in intestinal cancer. Cancer Discov. 10, 1590\u20131609 (2020).","journal-title":"Cancer Discov."},{"key":"1234_CR143","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1016\/j.cell.2023.11.004","volume":"186","author":"X Qin","year":"2023","unstructured":"Qin, X. et al. An oncogenic phenoscape of colonic stem cell polarization. Cell 186, 5554\u20135568.e5518 (2023).","journal-title":"Cell"},{"key":"1234_CR144","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/jcm9010128","volume":"9","author":"M Rebekah","year":"2020","unstructured":"Rebekah, M. et al. Patient-derived colorectal cancer organoids upregulate revival stem cell marker genes following chemotherapeutic treatment. J. Clin. Med. 9, 128 (2020).","journal-title":"J. Clin. Med."},{"key":"1234_CR145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41586-019-1154-y","volume":"569","author":"A Ayyaz","year":"2019","unstructured":"Ayyaz, A. et al. Single-cell transcriptomes of the regenerating intestine reveal a revival stem cell. Nature 569, 121\u2013125 (2019).","journal-title":"Nature"},{"key":"1234_CR146","first-page":"352ra108","volume":"8","author":"F Fan","year":"2016","unstructured":"Fan, F. et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 8, 352ra108 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1234_CR147","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12975-019-00702-1","volume":"10","author":"P Zhang","year":"2019","unstructured":"Zhang, P. et al. Exploration of MST1-mediated secondary brain injury induced by intracerebral hemorrhage in Rats via Hippo signaling pathway. Transl. Stroke Res. 10, 729\u2013743 (2019).","journal-title":"Transl. Stroke Res."},{"key":"1234_CR148","doi-asserted-by":"crossref","first-page":"11818","DOI":"10.1021\/acs.jmedchem.2c00926","volume":"65","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Discovery of IHMT-MST1-58 as a novel, potent, and selective MST1 inhibitor for the treatment of type 1\/2 diabetes. J. Med. Chem. 65, 11818\u201311839 (2022).","journal-title":"J. Med. Chem."},{"key":"1234_CR149","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23395-3","volume":"12","author":"N Kastan","year":"2021","unstructured":"Kastan, N. et al. Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues. Nat. Commun. 12, 3100 (2021).","journal-title":"Nat. Commun."},{"key":"1234_CR150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206113119","volume":"119","author":"NR Kastan","year":"2022","unstructured":"Kastan, N. R. et al. Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs. Proc. Natl Acad. Sci. 119, e2206113119 (2022).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1234_CR151","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.jbc.2022.101779","volume":"298","author":"A Aihara","year":"2022","unstructured":"Aihara, A. et al. Small molecule LATS kinase inhibitors block the Hippo signaling pathway and promote cell growth under 3D culture conditions. J. Biol. Chem. 298, 101779 (2022).","journal-title":"J. Biol. Chem."},{"key":"1234_CR152","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1039\/D4MD00492B","volume":"15","author":"G Issabayeva","year":"2024","unstructured":"Issabayeva, G. et al. Discovery of selective LATS inhibitors via scaffold hopping: enhancing drug-likeness and kinase selectivity for potential applications in regenerative medicine. RSC Med. Chem. 15, 4080\u20134089 (2024).","journal-title":"RSC Med. Chem."},{"key":"1234_CR153","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.stem.2024.03.003","volume":"31","author":"K Namoto","year":"2024","unstructured":"Namoto, K. et al. NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo. Cell Stem Cell 31, 554\u2013569.e517 (2024).","journal-title":"Cell Stem Cell"},{"key":"1234_CR154","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.stem.2024.03.017","volume":"31","author":"CL Burgess","year":"2024","unstructured":"Burgess, C. L. et al. Generation of human alveolar epithelial type I cells from pluripotent stem cells. Cell Stem Cell 31, 657\u2013675.e658 (2024).","journal-title":"Cell Stem Cell"},{"key":"1234_CR155","doi-asserted-by":"publisher","unstructured":"Dost, A. F. M. et al. A human organoid model of alveolar regeneration reveals distinct epithelial responses to interferon-gamma. Preprint at https:\/\/doi.org\/10.1101\/2025.01.30.635624 (2025).","DOI":"10.1101\/2025.01.30.635624"},{"key":"1234_CR156","doi-asserted-by":"crossref","first-page":"eabd6892","DOI":"10.1126\/scitranslmed.abd6892","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction. Sci. Transl. Med. 13, eabd6892 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1234_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/search?term=NCT06831825 (2025)."},{"key":"1234_CR158","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","volume":"150","author":"FX Yu","year":"2012","unstructured":"Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780\u2013791 (2012).","journal-title":"Cell"},{"key":"1234_CR159","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1083\/jcb.201501025","volume":"210","author":"NG Kim","year":"2015","unstructured":"Kim, N. G. & Gumbiner, B. M. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J. Cell Biol. 210, 503\u2013515 (2015).","journal-title":"J. Cell Biol."},{"key":"1234_CR160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","volume":"6","author":"GA Woodard","year":"2017","unstructured":"Woodard, G. A., Yang, Y. L., You, L. & Jablons, D. M. Drug development against the Hippo pathway in mesothelioma. Transl. Lung Cancer Res. 6, 335\u2013342 (2017).","journal-title":"Transl. Lung Cancer Res."},{"key":"1234_CR161","doi-asserted-by":"crossref","first-page":"eabb4778","DOI":"10.1126\/scisignal.abb4778","volume":"13","author":"T Dhanaraman","year":"2020","unstructured":"Dhanaraman, T. et al. RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway. Sci. Signal. 13, eabb4778 (2020).","journal-title":"Sci. Signal."},{"key":"1234_CR162","volume":"9","author":"MK Gill","year":"2018","unstructured":"Gill, M. K. et al. A feed forward loop enforces YAP\/TAZ signaling during tumorigenesis. Nat. Commun. 9, 3510 (2018).","journal-title":"Nat. Commun."},{"key":"1234_CR163","volume":"9","author":"WC Yuan","year":"2018","unstructured":"Yuan, W. C. et al. NUAK2 is a critical YAP target in liver cancer. Nat. Commun. 9, 4834 (2018).","journal-title":"Nat. Commun."},{"key":"1234_CR164","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2159-8290.CD-17-0533","volume":"8","author":"J Port","year":"2018","unstructured":"Port, J. et al. Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discov. 8, 632\u2013647 (2018).","journal-title":"Cancer Discov."},{"key":"1234_CR165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/EBC20240005","volume":"68","author":"GL Skalka","year":"2024","unstructured":"Skalka, G. L., Whyte, D., Lubawska, D. & Murphy, D. J. NUAK: never underestimate a kinase. Essays Biochem. 68, 295\u2013307 (2024).","journal-title":"Essays Biochem."},{"key":"1234_CR166","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.chembiol.2024.02.013","volume":"31","author":"K Graham","year":"2024","unstructured":"Graham, K. et al. Discovery of YAP1\/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell Chem. Biol. 31, 1247\u20131263.e1216 (2024).","journal-title":"Cell Chem. Biol."},{"issue":"Suppl. 13","key":"1234_CR167","doi-asserted-by":"crossref","first-page":"Abstr. ND11","DOI":"10.1158\/1538-7445.AM2021-ND11","volume":"81","author":"AR Macleod","year":"2021","unstructured":"Macleod, A. R. The discovery and characterization of ION-537: a next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models. Cancer Res. 81 (Suppl. 13), Abstr. ND11 (2021).","journal-title":"Cancer Res."},{"key":"1234_CR168","doi-asserted-by":"crossref","first-page":"15168","DOI":"10.1021\/acs.jmedchem.4c00815","volume":"67","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Exploring degradation of intrinsically disordered protein Yes-associated protein induced by proteolysis targeting chimeras. J. Med. Chem. 67, 15168\u201315198 (2024).","journal-title":"J. Med. Chem."},{"key":"1234_CR169","volume":"14","author":"IAM Barbosa","year":"2023","unstructured":"Barbosa, I. A. M. et al. Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens. Nat. Commun. 14, 3907 (2023).","journal-title":"Nat. Commun."},{"key":"1234_CR170","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","volume":"23","author":"AV Pobbati","year":"2015","unstructured":"Pobbati, A. V. et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure 23, 2076\u20132086 (2015).","journal-title":"Structure"},{"key":"1234_CR171","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nchembio.2036","volume":"12","author":"P Chan","year":"2016","unstructured":"Chan, P. et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat. Chem. Biol. 12, 282\u2013289 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"1234_CR172","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","volume":"24","author":"CL Noland","year":"2016","unstructured":"Noland, C. L. et al. Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure 24, 179\u2013186 (2016).","journal-title":"Structure"},{"key":"1234_CR173","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46531-1","volume":"15","author":"I Baroja","year":"2024","unstructured":"Baroja, I., Kyriakidis, N. C., Halder, G. & Moya, I. M. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer. Nat. Commun. 15, 2700 (2024).","journal-title":"Nat. Commun."},{"key":"1234_CR174","doi-asserted-by":"crossref","unstructured":"Brennan, D., Liang, Y., Mlynarski, S. & Zhu, B.-Y. in 2024 Medicinal Chemistry Reviews (vol. 59) Ch. 9, 175-201 (ACS, 2024).","DOI":"10.1021\/mc-2024-vol59.ch09"},{"key":"1234_CR175","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","volume":"48","author":"AV Pobbati","year":"2023","unstructured":"Pobbati, A. V., Kumar, R., Rubin, B. P. & Hong, W. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem. Sci. 48, 450\u2013462 (2023).","journal-title":"Trends Biochem. Sci."},{"key":"1234_CR176","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e516 (2017).","journal-title":"Cell"},{"key":"1234_CR177","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","volume":"20","author":"TT Tang","year":"2021","unstructured":"Tang, T. T. et al. Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol. Cancer Ther. 20, 986\u2013998 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1234_CR178","volume":"184","author":"W Lu","year":"2019","unstructured":"Lu, W. et al. Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors. Eur. J. Med. Chem. 184, 111767 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"1234_CR179","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.stem.2020.03.002","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Lats1\/2 sustain intestinal stem cells and Wnt activation through TEAD-dependent and independent transcription. Cell Stem Cell 26, 675\u2013692.e678 (2020).","journal-title":"Cell Stem Cell"},{"key":"1234_CR180","first-page":"4399","volume":"10","author":"A Kaneda","year":"2020","unstructured":"Kaneda, A. et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am. J. Cancer Res. 10, 4399\u20134415 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"1234_CR181","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.1021\/acs.jmedchem.2c00403","volume":"65","author":"T Heinrich","year":"2022","unstructured":"Heinrich, T. et al. Optimization of TEAD P-site binding fragment hit into in vivo active lead MSC-4106. J. Med. Chem. 65, 9206\u20139229 (2022).","journal-title":"J. Med. Chem."},{"key":"1234_CR182","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1021\/acs.jmedchem.2c01548","volume":"66","author":"W Lu","year":"2023","unstructured":"Lu, W. et al. Structure-based design of Y-shaped covalent TEAD inhibitors. J. Med. Chem. 66, 4617\u20134632 (2023).","journal-title":"J. Med. Chem."},{"key":"1234_CR183","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0681","volume":"23","author":"H Hillen","year":"2024","unstructured":"Hillen, H. et al. A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models. Mol. Cancer Ther. 23, 3\u201313 (2024).","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl. 7","key":"1234_CR184","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1538-7445.AM2023-1646","volume":"83","author":"N Young","year":"2023","unstructured":"Young, N. et al. Abstract 1646: IK-930, a paralog-selective TEAD inhibitor for treating YAP\/TAZ-TEAD dependent cancers. Cancer Res. 83 (Suppl. 7), 1646 (2023).","journal-title":"Cancer Res."},{"issue":"Suppl. 6","key":"1234_CR185","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1538-7445.AM2024-6589","volume":"84","author":"JA Gordon","year":"2024","unstructured":"Gordon, J. A. et al. Abstract 6589: Discovery of potent and selective pan-TEAD autopalmitoylation inhibitors for the treatment of Hippo-pathway altered cancers. Cancer Res. 84 (Suppl. 6), 6589 (2024).","journal-title":"Cancer Res."},{"issue":"Suppl. 7","key":"1234_CR186","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1158\/1538-7445.AM2023-4976","volume":"83","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Abstract 4976: Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential. Cancer Res. 83 (Suppl. 7), 4976 (2023).","journal-title":"Cancer Res."},{"issue":"Suppl. 6","key":"1234_CR187","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1158\/1538-7445.AM2024-7575","volume":"84","author":"X Han","year":"2024","unstructured":"Han, X. et al. Abstract 7575: BPI-460372, a covalent, irreversible TEAD inhibitor in phase I clinical development. Cancer Res. 84 (Suppl. 6), 7575 (2024).","journal-title":"Cancer Res."},{"issue":"Suppl. 6","key":"1234_CR188","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1158\/1538-7445.AM2024-7264","volume":"84","author":"P-Y Chen","year":"2024","unstructured":"Chen, P.-Y. et al. Abstract 7264: OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models. Cancer Res. 84 (Suppl. 6), 7264 (2024).","journal-title":"Cancer Res."},{"issue":"Suppl. 6","key":"1234_CR189","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1158\/1538-7445.AM2024-7265","volume":"84","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. Abstract 7265: ETS-005, a highly selective TEAD4 palmitoylation inhibitor with potent anti-tumor activity and brain penetrating capability. Cancer Res. 84 (Suppl. 6), 7265 (2024).","journal-title":"Cancer Res."},{"issue":"Suppl. 6","key":"1234_CR190","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1538-7445.AM2024-5913","volume":"84","author":"F Muller","year":"2024","unstructured":"Muller, F., Kunnimalaiyaan, S., Mangrolia, P. & Olson, J. Abstract 5913: TEAD1\/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity. Cancer Res. 84 (Suppl. 6), 5913 (2024).","journal-title":"Cancer Res."},{"key":"1234_CR191","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1021\/acs.jmedchem.4c01393","volume":"67","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. Pan-transcriptional enhanced associated domain palmitoylation pocket covalent inhibitor. J. Med. Chem. 67, 18957\u201318968 (2024).","journal-title":"J. Med. Chem."},{"key":"1234_CR192","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-23-0538","volume":"23","author":"CJ Moure","year":"2024","unstructured":"Moure, C. J. et al. Activation of hepatocyte growth factor\/MET signaling as a mechanism of acquired resistance to a novel YAP1\/TEAD small molecule inhibitor. Mol. Cancer Ther. 23, 1095\u20131108 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1234_CR193","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1021\/acs.jmedchem.4c01949","volume":"68","author":"T Heinrich","year":"2025","unstructured":"Heinrich, T. et al. MoA studies of the TEAD P-site binding ligand MSC-4106 and its optimization to TEAD1-selective amide M3686. J. Med. Chem. 68, 6149\u20136164 (2025).","journal-title":"J. Med. Chem."},{"key":"1234_CR194","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122.e112 (2020).","journal-title":"Cancer Cell"},{"key":"1234_CR195","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.chembiol.2018.11.010","volume":"26","author":"K Bum-Erdene","year":"2019","unstructured":"Bum-Erdene, K. et al. Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD\u22c5Yap protein-protein interaction. Cell Chem. Biol. 26, 378\u2013389.e313 (2019).","journal-title":"Cell Chem. Biol."},{"issue":"Suppl. 8","key":"1234_CR196","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of Yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res. 83 (Suppl. 8), CT006 (2023).","journal-title":"Cancer Res."},{"key":"1234_CR197","doi-asserted-by":"crossref","unstructured":"Yap, T. A. et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of Yes-Associated Protein (YAP)\/Transcriptional EnhancerActivator Domain (TEAD), in patients with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. AACR Annual Meeting 2023 https:\/\/vivacetherapeutics.com\/wp-content\/uploads\/Vivace-Therapeutics-2023-AACR-Presentation.pdf (2023).","DOI":"10.1158\/1538-7445.AM2023-CT006"},{"key":"1234_CR198","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300\u20131305 (2012).","journal-title":"Genes Dev."},{"key":"1234_CR199","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/cbic.201300163","volume":"14","author":"JC Hau","year":"2013","unstructured":"Hau, J. C. et al. The TEAD4-YAP\/TAZ protein-protein interaction: expected similarities and unexpected differences. Chembiochem 14, 1218\u20131225 (2013).","journal-title":"Chembiochem"},{"key":"1234_CR200","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/ml500160m","volume":"5","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z. et al. Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. ACS Med. Chem. Lett. 5, 993\u2013998 (2014).","journal-title":"ACS Med. Chem. Lett."},{"key":"1234_CR201","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25068","volume":"6","author":"Y Mesrouze","year":"2017","unstructured":"Mesrouze, Y. et al. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD. eLife 6, e25068 (2017).","journal-title":"eLife"},{"key":"1234_CR202","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.bmcl.2019.06.022","volume":"29","author":"P Furet","year":"2019","unstructured":"Furet, P. et al. Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence. Bioorg. Med. Chem. Lett. 29, 2316\u20132319 (2019).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1234_CR203","volume":"17","author":"P Furet","year":"2022","unstructured":"Furet, P. et al. The first class of small molecules potently disrupting the YAP-TEAD interaction by direct competition. ChemMedChem 17, e202200303 (2022).","journal-title":"ChemMedChem"},{"key":"1234_CR204","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1021\/acschembio.2c00936","volume":"18","author":"Y Mesrouze","year":"2023","unstructured":"Mesrouze, Y. et al. Biochemical and structural characterization of a peptidic inhibitor of the YAP:TEAD interaction that binds to the \u03b1-Helix pocket on TEAD. ACS Chem. Biol. 18, 643\u2013651 (2023).","journal-title":"ACS Chem. Biol."},{"key":"1234_CR205","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300051","volume":"18","author":"H Sellner","year":"2023","unstructured":"Sellner, H. et al. Optimization of a class of dihydrobenzofurane analogs toward orally efficacious YAP-TEAD protein-protein interaction inhibitors. ChemMedChem 18, e202300051 (2023).","journal-title":"ChemMedChem"},{"key":"1234_CR206","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau, E. A. et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat. Cancer 5, 1102\u20131120 (2024).","journal-title":"Nat. Cancer"},{"key":"1234_CR207","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1538-7445.AM2024-4585","volume":"84","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. Abstract 4585: discovery of ETS-006, a highly potent YAP\/TEADs PPI inhibitor with broad anti-tumor activity as a single agent. Cancer Res. 84, 4585(2024).","journal-title":"Cancer Res."},{"key":"1234_CR208","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.0c01275","volume":"63","author":"H Karatas","year":"2020","unstructured":"Karatas, H. et al. Discovery of covalent inhibitors targeting the transcriptional enhanced associate domain central pocket. J. Med. Chem. 63, 11972\u201311989 (2020).","journal-title":"J. Med. Chem."},{"issue":"Suppl. 7","key":"1234_CR209","doi-asserted-by":"crossref","first-page":"LB029","DOI":"10.1158\/1538-7445.AM2024-LB029","volume":"84","author":"R Sawant","year":"2024","unstructured":"Sawant, R. et al. Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders. Cancer Res. 84 (Suppl. 7), LB029 (2024).","journal-title":"Cancer Res."},{"key":"1234_CR210","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/acs.jmedchem.4c02884","volume":"68","author":"Y Lu","year":"2025","unstructured":"Lu, Y. et al. Selective degradation of TEADs by a PROTAC molecule exhibited robust anticancer efficacy in vitro and in vivo. J. Med. Chem. 68, 5616\u20135640 (2025).","journal-title":"J. Med. Chem."},{"key":"1234_CR211","volume":"10","author":"H Chen","year":"2024","unstructured":"Chen, H. et al. Targeted degradation of specific TEAD paralogs by small molecule degraders. Heliyon 10, e37829 (2024).","journal-title":"Heliyon"},{"key":"1234_CR212","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acsmedchemlett.4c00029","volume":"15","author":"H Li","year":"2024","unstructured":"Li, H. et al. Design, synthesis, and bioevaluation of transcriptional enhanced assocciated domain (TEAD) PROTAC degraders. ACS Med. Chem. Lett. 15, 631\u2013639 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"1234_CR213","first-page":"932","volume":"8","author":"X Deng","year":"2018","unstructured":"Deng, X. & Fang, L. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs. Am. J. Cancer Res. 8, 932\u2013943 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"1234_CR214","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1101\/gad.350127.122","volume":"36","author":"J Cai","year":"2022","unstructured":"Cai, J. et al. YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP. Genes Dev. 36, 1119\u20131128 (2022).","journal-title":"Genes Dev."},{"key":"1234_CR215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/ph16040583","volume":"16","author":"B Zhao","year":"2023","unstructured":"Zhao, B., Pobbati, A. V., Rubin, B. P. & Stauffer, S. Leveraging hot spots of TEAD-coregulator interactions in the design of direct small molecule protein-protein interaction disruptors targeting Hippo pathway signaling. Pharmaceuticals 16, 583 (2023).","journal-title":"Pharmaceuticals"},{"key":"1234_CR216","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","volume":"25","author":"S Jiao","year":"2014","unstructured":"Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166\u2013180 (2014).","journal-title":"Cancer Cell"},{"key":"1234_CR217","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/s44319-024-00217-3","volume":"25","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni, A. et al. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO Rep. 25, 3944\u20133969 (2024).","journal-title":"EMBO Rep."},{"key":"1234_CR218","doi-asserted-by":"publisher","unstructured":"Guarnaccia, A. D. et al. TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway. Preprint at https:\/\/doi.org\/10.1101\/2024.11.15.623512 (2024).","DOI":"10.1101\/2024.11.15.623512"},{"key":"1234_CR219","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1078-0432.CCR-22-2497","volume":"29","author":"CN Seavey","year":"2023","unstructured":"Seavey, C. N. et al. Loss of CDKN2A cooperates with WWTR1(TAZ)-CAMTA1 gene fusion to promote tumor progression in epithelioid hemangioendothelioma. Clin. Cancer Res. 29, 2480\u20132493 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1234_CR220","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/gutjnl-2023-329686","volume":"73","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut 73, 1280\u20131291 (2024).","journal-title":"Gut"},{"key":"1234_CR221","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2023.02.043","volume":"164","author":"Y Saito","year":"2023","unstructured":"Saito, Y. et al. A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23. Gastroenterology 164, 1279\u20131292 (2023).","journal-title":"Gastroenterology"},{"key":"1234_CR222","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107809","volume":"31","author":"JK Holden","year":"2020","unstructured":"Holden, J. K. et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of Hippo pathway signaling. Cell Rep. 31, 107809 (2020).","journal-title":"Cell Rep."},{"key":"1234_CR223","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217467","volume":"612","author":"K Sato","year":"2025","unstructured":"Sato, K. et al. Targeting YAP\/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. Cancer Lett. 612, 217467 (2025).","journal-title":"Cancer Lett."},{"key":"1234_CR224","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37147-y","volume":"14","author":"S Murakami","year":"2023","unstructured":"Murakami, S., White, S. M., McIntosh, A. T., Nguyen, C. D. K. & Yi, C. Spontaneously evolved progenitor niches escape Yap oncogene addiction in advanced pancreatic ductal adenocarcinomas. Nat. Commun. 14, 1443 (2023).","journal-title":"Nat. Commun."},{"key":"1234_CR225","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/neuonc\/noab244","volume":"24","author":"AM Barrette","year":"2022","unstructured":"Barrette, A. M. et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 24, 694\u2013707 (2022).","journal-title":"Neuro Oncol."},{"key":"1234_CR226","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awac342","volume":"146","author":"L Laraba","year":"2023","unstructured":"Laraba, L. et al. Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. Brain 146, 1697\u20131713 (2023).","journal-title":"Brain"},{"key":"1234_CR227","unstructured":"Press release: Ikena Oncology shares initial positive and differentiated dose escalation data from IK-930 phase I trial and reports third quarter 2023 financial results. Ikena Oncology https:\/\/ir.ikenaoncology.com\/node\/7936\/pdf (2023)."},{"key":"1234_CR228","unstructured":"Press Release: Ikena Oncology announes strategic update. Ikena Oncology https:\/\/ir.ikenaoncology.com\/node\/8131\/pdf (2024)."},{"issue":"Suppl. 6","key":"1234_CR229","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1158\/1538-7445.AM2024-7282","volume":"84","author":"TT Tang","year":"2024","unstructured":"Tang, T. T. & Post, L. Abstract 7282: Comparing TEAD palmitoylation inhibitors with differential TEAD selectivity in combination efficacy with targeted therapies and in renal safety. Cancer Res. 84 (Suppl. 6), 7282 (2024).","journal-title":"Cancer Res."},{"key":"1234_CR230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.devcel.2019.05.024","volume":"50","author":"M Hashimoto","year":"2019","unstructured":"Hashimoto, M. & Sasaki, H. Epiblast formation by TEAD-YAP-dependent expression of pluripotency factors and competitive elimination of unspecified cells. Dev. Cell 50, 139\u2013154.e135 (2019).","journal-title":"Dev. Cell"},{"key":"1234_CR231","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.mod.2007.11.002","volume":"125","author":"N Nishioka","year":"2008","unstructured":"Nishioka, N. et al. Tead4 is required for specification of trophectoderm in pre-implantation mouse embryos. Mech. Dev. 125, 270\u2013283 (2008).","journal-title":"Mech. Dev."},{"key":"1234_CR232","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1128\/MCB.01759-07","volume":"28","author":"A Sawada","year":"2008","unstructured":"Sawada, A. et al. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol. Cell Biol. 28, 3177\u20133189 (2008).","journal-title":"Mol. Cell Biol."},{"key":"1234_CR233","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1101\/gad.8.19.2293","volume":"8","author":"Z Chen","year":"1994","unstructured":"Chen, Z., Friedrich, G. A. & Soriano, P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev. 8, 2293\u20132301 (1994).","journal-title":"Genes Dev."},{"key":"1234_CR234","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/dvg.20330","volume":"45","author":"KJ Kaneko","year":"2007","unstructured":"Kaneko, K. J., Kohn, M. J., Liu, C. & DePamphilis, M. L. Transcription factor TEAD2 is involved in neural tube closure. Genesis 45, 577\u2013587 (2007).","journal-title":"Genesis"},{"key":"1234_CR235","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1242\/dev.010223","volume":"134","author":"R Yagi","year":"2007","unstructured":"Yagi, R. et al. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. Development 134, 3827\u20133836 (2007).","journal-title":"Development"},{"key":"1234_CR236","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fcell.2019.00156","volume":"7","author":"S Kakiuchi-Kiyota","year":"2019","unstructured":"Kakiuchi-Kiyota, S., Schutten, M. M., Zhong, Y., Crawford, J. J. & Dey, A. Safety considerations in the development of Hippo pathway inhibitors in cancers. Front. Cell Dev. Biol. 7, 156 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"1234_CR237","doi-asserted-by":"crossref","first-page":"F241","DOI":"10.1152\/ajprenal.00500.2015","volume":"311","author":"JS Wong","year":"2016","unstructured":"Wong, J. S., Meliambro, K., Ray, J. & Campbell, K. N. Hippo signaling in the kidney: the good and the bad. Am. J. Physiol. Ren. Physiol. 311, F241\u2013F248 (2016).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1234_CR238","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.2014090916","volume":"27","author":"M Schwartzman","year":"2016","unstructured":"Schwartzman, M. et al. Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J. Am. Soc. Nephrol. 27, 216\u2013226 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR239","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1152\/ajprenal.00426.2021","volume":"322","author":"J Chen","year":"2022","unstructured":"Chen, J., Wang, X., He, Q. & Harris, R. C. TAZ is important for maintenance of the integrity of podocytes. Am. J. Physiol. Ren. Physiol. 322, F419\u2013F428 (2022).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1234_CR240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","volume":"83","author":"H Pavenst\u00e4dt","year":"2003","unstructured":"Pavenst\u00e4dt, H., Kriz, W. & Kretzler, M. Cell biology of the glomerular podocyte. Physiol. Rev. 83, 253\u2013307 (2003).","journal-title":"Physiol. Rev."},{"key":"1234_CR241","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1681\/ASN.2020020220","volume":"31","author":"JJ Chung","year":"2020","unstructured":"Chung, J. J. et al. Single-cell transcriptome profiling of the kidney glomerulus identifies key cell types and reactions to injury. J. Am. Soc. Nephrol. 31, 2341\u20132354 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR242","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.kint.2024.01.038","volume":"105","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Inhibition of transcriptional coactivator YAP impairs the expression and function of transcription factor WT1 in diabetic podocyte injury. Kidney Int. 105, 1200\u20131211 (2024).","journal-title":"Kidney Int."},{"key":"1234_CR243","doi-asserted-by":"crossref","first-page":"eaaf8165","DOI":"10.1126\/scisignal.aaf8165","volume":"10","author":"MM Rinschen","year":"2017","unstructured":"Rinschen, M. M. et al. YAP-mediated mechanotransduction determines the podocyte\u2019s response to damage. Sci. Signal. 10, eaaf8165 (2017).","journal-title":"Sci. Signal."},{"key":"1234_CR244","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.625762","volume":"12","author":"KE Haley","year":"2021","unstructured":"Haley, K. E. et al. YAP translocation precedes cytoskeletal rearrangement in podocyte stress response: a podometric investigation of diabetic nephropathy. Front. Physiol. 12, 625762 (2021).","journal-title":"Front. Physiol."},{"key":"1234_CR245","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1158\/1538-7445.AM2019-3086","volume":"79","author":"A Kaneda","year":"2019","unstructured":"Kaneda, A. et al. Abstract 3086: discovery of a first-in-class TEAD inhibitor which directly inhibits YAP\/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma. Cancer Res. 79, 3086 (2019).","journal-title":"Cancer Res."},{"key":"1234_CR246","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trecan.2024.10.004","volume":"11","author":"S Paul","year":"2024","unstructured":"Paul, S., Sims, J., Pham, T. & Dey, A. Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors? Trends Cancer 11, 25\u201336 (2024).","journal-title":"Trends Cancer"},{"key":"1234_CR247","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2131\/jts.49.175","volume":"49","author":"H Otsuki","year":"2024","unstructured":"Otsuki, H. et al. Reversible and monitorable nephrotoxicity in rats by the novel potent transcriptional enhanced associate domain (TEAD) inhibitor, K-975. J. Toxicol. Sci. 49, 175\u2013191 (2024).","journal-title":"J. Toxicol. Sci."},{"key":"1234_CR248","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells. Nat. Commun. 13, 6744 (2022).","journal-title":"Nat. Commun."},{"key":"1234_CR249","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1535-7163.MCT-24-0308","volume":"24","author":"K Akao","year":"2025","unstructured":"Akao, K. et al. TEAD-independent cell growth of Hippo-inactive mesothelioma cells: unveiling resistance to TEAD inhibitor K-975 through MYC signaling activation. Mol. Cancer Ther. 24, 709\u2013719 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1234_CR250","volume":"16","author":"S Paul","year":"2025","unstructured":"Paul, S. et al. Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition. Nat. Commun. 16, 1743 (2025).","journal-title":"Nat. Commun."},{"key":"1234_CR251","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acschembio.5c00162","volume":"20","author":"K Nutsch","year":"2025","unstructured":"Nutsch, K. et al. Augmented acyl-CoA biosynthesis promotes resistance to TEAD palmitoylation site inhibition. ACS Chem. Biol. 20, 967\u2013975 (2025).","journal-title":"ACS Chem. Biol."},{"key":"1234_CR252","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","volume":"49","author":"SM White","year":"2019","unstructured":"White, S. M. et al. YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. Dev. Cell 49, 425\u2013443.e429 (2019).","journal-title":"Dev. Cell"},{"key":"1234_CR253","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/0008-5472.CAN-19-1415","volume":"79","author":"GE Coggins","year":"2019","unstructured":"Coggins, G. E. et al. YAP1 mediates resistance to MEK1\/2 inhibition in neuroblastomas with hyperactivated RAS signaling. Cancer Res. 79, 6204\u20136214 (2019).","journal-title":"Cancer Res."},{"key":"1234_CR254","doi-asserted-by":"crossref","first-page":"eaaz4589","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson, M. B. et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci. Transl. Med. 12, eaaz4589 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1234_CR255","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13771-5","volume":"11","author":"T Tsuji","year":"2020","unstructured":"Tsuji, T. et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11, 74 (2020).","journal-title":"Nat. Commun."},{"issue":"Suppl. 12","key":"1234_CR256","doi-asserted-by":"crossref","first-page":"B088","DOI":"10.1158\/1535-7163.TARG-23-B088","volume":"22","author":"TT Tang","year":"2023","unstructured":"Tang, T. T. & Post, L. Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K\/AKT\/mTOR pathways. Mol. Cancer Ther. 22 (Suppl. 12), B088 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"1234_CR257","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards, A. C. et al. TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 83, 4112\u20134129 (2023).","journal-title":"Cancer Res."},{"key":"1234_CR258","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1535-7163.MCT-23-0371","volume":"23","author":"T Ogimoto","year":"2024","unstructured":"Ogimoto, T. et al. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation\u2013positive lung cancer. Mol. Cancer Ther. 23, 564\u2013576 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1234_CR259","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk, F. et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat. Commun. 15, 3741 (2024).","journal-title":"Nat. Commun."},{"key":"1234_CR260","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"1234_CR261","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114752","volume":"211","author":"A Schirmer","year":"2024","unstructured":"Schirmer, A. et al. 234 (PB222): Rational combination of pan-TEAD inhibitor SW-682 and MEK inhibitor mirdametinib in head and neck squamous cell carcinomas leads to synergistic response. Eur. J. Cancer 211, 114752 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1234_CR262","volume":"211","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. 39 (PB027): TEAD inhibition by SW-682 potentiates activity of targeted therapies in NSCLC models. Eur. J. Cancer 211, 114567 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1234_CR263","volume":"11","author":"L Hu","year":"2022","unstructured":"Hu, L. et al. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode. eLife 11, e80210 (2022).","journal-title":"eLife"},{"key":"1234_CR264","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2174\/0113892002351556250123105344","volume":"25","author":"X Liu","year":"2025","unstructured":"Liu, X. et al. In vitro and in vivo drug metabolism analysis of BPI-460372 - a covalent TEAD1\/3\/4 inhibitor. Curr. Drug Metab. 25, 754\u2013768 (2025).","journal-title":"Curr. Drug Metab."},{"key":"1234_CR265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0955-0674(96)80066-4","volume":"8","author":"CJ Marshall","year":"1996","unstructured":"Marshall, C. J. Ras effectors. Curr. Opin. Cell Biol. 8, 197 (1996).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1234_CR266","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","volume":"4","author":"Y Adachi","year":"2023","unstructured":"Adachi, Y. et al. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat. Cancer 4, 829\u2013843 (2023).","journal-title":"Nat. Cancer"},{"key":"1234_CR267","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.devcel.2017.08.013","volume":"42","author":"J Pascual","year":"2017","unstructured":"Pascual, J. et al. Hippo reprograms the transcriptional response to Ras signaling. Dev. Cell 42, 667\u2013680.e664 (2017).","journal-title":"Dev. Cell"},{"key":"1234_CR268","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1016\/j.cub.2024.07.060","volume":"34","author":"KA Mitchell","year":"2024","unstructured":"Mitchell, K. A. et al. The JNK and Hippo pathways control epithelial integrity and prevent tumor initiation by regulating an overlapping transcriptome. Curr. Biol. 34, 3966\u20133982.e3967 (2024).","journal-title":"Curr. Biol."},{"key":"1234_CR269","volume":"11","author":"C Stein","year":"2015","unstructured":"Stein, C. et al. YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers. PLoS Genet. 11, e1005465 (2015).","journal-title":"PLoS Genet."},{"key":"1234_CR270","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-20-0706","volume":"11","author":"TH Pham","year":"2021","unstructured":"Pham, T. H. et al. Machine-learning and chemicogenomics approach defines and predicts cross-talk of Hippo and MAPK pathways. Cancer Discov. 11, 778\u2013793 (2021).","journal-title":"Cancer Discov."},{"key":"1234_CR271","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1158\/0008-5472.CAN-20-0907","volume":"80","author":"J Park","year":"2020","unstructured":"Park, J. et al. YAP and AP-1 cooperate to initiate pancreatic cancer development from ductal cells in mice. Cancer Res. 80, 4768\u20134779 (2020).","journal-title":"Cancer Res."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01234-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:03:56Z","timestamp":1761829436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01234-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":271,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1038\/s41573-025-01234-0","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"29 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.T.T. reports employment with Vivace Therapeutics and has equity interest in Vivace Therapeutics. K.F.H. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}